Perspective Therapeutics CATX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $21.37M-35.1% | $32.92M+61.9% | $20.34M+22.4% | $16.62M+16.0% | $14.33M+11.2% | ||
| $6.99M+0.5% | $6.95M-10.1% | $7.73M+0.3% | $7.71M-1.7% | $7.84M-4.9% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $28.36M-28.9% | $39.88M+42.1% | $28.07M+15.4% | $24.33M+9.7% | $22.17M-51.0% | ||
| $28.36M-28.9% | $39.88M+42.1% | $28.07M+15.4% | $24.33M+9.7% | $22.17M-51.0% | ||
| -$28.28M+29.0% | -$39.83M-43.0% | -$27.86M-15.9% | -$24.04M-10.1% | -$21.83M+51.5% | ||
| $2.2M+36.1% | $1.61M-17.5% | $1.96M-9.4% | $2.16M-9.4% | $2.38M-9.9% | ||
| $2.09M+35.1% | $1.55M-18.1% | $1.89M-7.3% | $2.04M-44.2% | $3.66M+34.5% | ||
| —— | -$38.28M-47.4% | -$25.97M-18.0% | -$22M-21.0% | -$18.18M+57.0% | ||
| -$26.19M+30.1% | -$37.49M-44.4% | -$25.97M-20.9% | -$21.49M-18.2% | -$18.18M+54.7% | ||
| —— | $0— | $0-100% | $514K— | $0— | ||
| -$0.25+51.0% | -$0.51-45.7% | -$0.35-20.7% | -$0.29-16.0% | -$0.25+59.0% | ||
| -$0.25+51.0% | -$0.51-45.7% | -$0.35-20.7% | -$0.29-16.0% | -$0.25+59.0% | ||
| 103.6M+40.4% | 73.8M-0.7% | 74.3M+0.1% | 74.2M+2.6% | 72.4M+12.3% | ||
| 103.6M+40.4% | 73.8M-0.7% | 74.3M+0.1% | 74.2M+2.6% | 72.4M+12.3% | ||
| $105K+64.1% | $64K-1.5% | $65K-45.4% | $119K-7.0% | $128K— | ||
| -$26.53M+29.3% | -$37.49M-45.0% | -$25.86M-20.3% | -$21.5M-18.7% | -$18.11M+55.0% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| -$336K— | $0-100% | $111K+794% | -$16K-123% | $70K+237% | ||
| $0— | $0— | $0— | $0-100% | $1.4M— | ||
| $76K+76.7% | $43K-79.4% | $209K-27.9% | $290K-15.2% | $342K+46.2% | ||
| -$28.28M+29.0% | -$39.83M-43.0% | -$27.86M-15.9% | -$24.04M-10.1% | -$21.83M+51.5% | ||
| -$27.16M+30.1% | -$38.82M-43.3% | -$27.09M-16.2% | -$23.31M-10.5% | -$21.1M+52.3% | ||
| -$27.16M+30.1% | -$38.82M-43.3% | -$27.09M-16.2% | -$23.31M-10.5% | -$21.1M+52.3% | ||
| -$28.28M+29.0% | -$39.83M-43.0% | -$27.86M-15.9% | -$24.04M-10.1% | -$21.83M+51.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Perspective Therapeutics's revenue?
- Perspective Therapeutics (CATX) generated $10.0M in revenue over the trailing twelve months, up 0.5% year over year.
- Is Perspective Therapeutics profitable?
- Perspective Therapeutics is not currently profitable: it reported a net loss of $111.1M over the trailing twelve months, a -218.4% net margin.
- What are Perspective Therapeutics's profit margins?
- Gross margin is 33.1% and operating margin is -292.7%, with a -218.4% net margin.
- What is Perspective Therapeutics's earnings per share?
- Perspective Therapeutics's diluted EPS over the trailing twelve months is $-1.40.
- Where does Perspective Therapeutics's income statement data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
